MANILA – Pharmaceutical firm AstraZeneca has expressed interest in conducting its Phase 3 clinical trial in the Philippines.
Department of Science and Technology (DOST)-Philippine Council for Health Research and Development executive director Jaime Montoya said the company has already signed the Confidentiality Disclosure Agreement that would allow the Philippines’ Vaccine Expert Panel (VEP) to check the data on its Phase 1 and 2 clinical trials for its Covid-19 vaccine.
The VEP, after checking the data, would then recommend to the Ethics Review Committee and the Food and Drug Administration (FDA) the conduct of the clinical trial in the country.
Montoya said for now, the VEP bases its evaluation from the documents AstraZeneca has initially submitted. He said the VEP has completed its initial evaluation and has already sent questions to AstraZeneca.
“If they could answer all those questions, the VEP could then recommend the conduct of the clinical trial to the Ethics Review Committee, and the FDA which has the final decision on whether the clinical trial can be done here or not,” he said.
Montoya said AstraZeneca or any pharmaceutical firm would have to seek the Philippine FDA’s approval, even if they have already got the US FDA nod or emergency use authorization from other countries.
He advised people who have questions about the firm’s vaccine’s effectivity to wait for the official publication of AstraZeneca’s data.
Montoya also disclosed that pharmaceutical firm, Pfizer, will not conduct a clinical trial in the Philippines for its Covid-19 vaccine.
He, however, said the country is still negotiating with Pfizer for the supply of its Covid-19 vaccine.